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Abstract Latest results on the action of adenosine A2A
receptor antagonists indicate their potential therapeutic
usefulness in the treatment of Parkinson’s disease. Basal
ganglia possess high levels of adenosine A2A receptors,
mainly on the external surfaces of neurons located at the
indirect tracts between the striatum, globus pallidus, and
substantia nigra. Experiments with animal models of
Parkinson’s disease indicate that adenosine A2A receptors
are strongly involved in the regulation of the central
nervous system. Co-localization of adenosine A2A and
dopaminergic D2 receptors in striatum creates a milieu for
antagonistic interaction between adenosine and dopamine.
The experimental data prove that the best improvement of
mobility in patients with Parkinson’s disease could be
achieved with simultaneous activation of dopaminergic D2
receptors and inhibition of adenosine A2A receptors. In
animal models of Parkinson’s disease, the use of selective
antagonists of adenosine A2A receptors, such as istradefyl-
line, led to the reversibility of movement dysfunction.
These compounds might improve mobility during both
monotherapy and co-administration with L-DOPA and
dopamine receptor agonists. The use of adenosine A2A
receptor antagonists in combination therapy enables the
reduction of the L-DOPA doses, as well as a reduction of
side effects. In combination therapy, the adenosine A2A
receptor antagonists might be used in both moderate and
advanced stages of Parkinson’s disease. The long-lasting
administration of adenosine A2A receptor antagonists does
not decrease the patient response and does not cause side
effects typical of L-DOPA therapy. It was demonstrated in
various animal models that inhibition of adenosine A2A
receptors not only decreases the movement disturbance, but
also reveals a neuroprotective activity, which might impede
or stop the progression of the disease. Recently, clinical
trials were completed on the use of istradefylline (KW-
6002), an inhibitor of adenosine A2A receptors, as an anti-
Parkinson drug.
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Introduction
In Parkinson’s disease, which belongs to the family of
neurodegenerative disorders, the progressive damage of
dopaminergic neurons in the substantia nigra is the cardinal
pathophysiological event, which leads to a substantial
reduction in the dopamine concentration in striatum. This
reduction is responsible for the major symptoms of the
disease, such as bradykinesia, muscular rigidity, and tremor.
The clinical symptoms appear after approximately 60% of
the dopaminergic neurons are damaged, and the dopamine
concentration in the striatum drops by about 80%. The
neuronal degeneration is observed especially in the ven-
tralis region of the pars compacta, substantia nigra, and
locus caeruleus. The eosinofilic inclusion bodies, called the
Lewy bodies, occur in many damaged neurons. The
etiology of Parkinson’s disease is still unknown, although
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free radicals is postulated. Up to now, 11 types of familial
Parkinsonism have been described. Of those, the mutation
of the α-synuclein gene (PARK1) in chromosome 4 was
identified first.
The major drugs used in the treatment are the dopamine
precursor L-DOPA (L-3,4-dihydroxyphenylalanine) and
dopaminergic receptor agonists. Other drugs are cholino-
lytic compounds; the catechol-O-methyltransferase inhib-
itors (COMT); drugs that increase the release of dopamine,
such as amantadine, which is also an antagonist of
glutaminergic receptors; as well as inhibitors of mono-
aminooxidase type B.
The agonists of D2/D3 dopaminergic receptors newly
introduced into clinical use (e.g., pramipexole and ropinir-
ole) reveal a 20–30 times greater affinity for D3 than D2
receptors. All of these drugs are highly efficient in early
stages of the disease [1, 2]. However, long-term treatment
with L-DOPA leads to its decreased efficacy and the
occurrence of side effects, including dyskinesias, “on”
phase shortening, occurrence of “on-off” syndromes and
psychotic symptoms [1, 2]. The dopaminergic receptor
agonists, especially at the beginning of the treatment, might
cause the acute side effects, such as nausea and vomiting,
while lowering the blood pressure. Their long-term use also
results in lowering of the drug efficacy, development of
dyskinesias, and progression of the disease [1]. It should be
emphasized that all the drugs mentioned above act
symptomatically and do not significantly impede the
disease progression.
So far there is no efficient strategy to counteract the
progressive death of the dopaminergic neurons of the
substantia nigra [3]. Experiments have shown that dopamine,
MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), or
oxidation products of 6-hydroxydopamine (6-OHDA) might
be responsible for the neuron death [4–6]. Therefore, the
search continues for new drugs for alleviating the disease
that do not cause dyskinesias and reveal a long-term clinical
efficacy. It is expected that new drugs would also impede or
stop the disease progression by a neuroprotective action.
Adenosine, dopamine, and their receptors in CNS
All sub-types of adenosine receptors, i.e., A1,A 2A,A 2B and
A3, have been detected in the central nervous system
(CNS). These receptors are glycoproteins that cooperate
with the G proteins [7–9].
Adenosine A1 and A2A receptors are characterized by
high affinity for adenosine, while A2B and A3 receptors
show significantly lower affinity for adenosine. Activation
of adenosine A1 receptors occurs at 0.3–3 nM concentration
of adenosine, adenosine A2A receptors at 1–20 nM, while
adenosine A2B or A3 receptor activation requires an agonist
concentration larger than 1 μM[ 7]. Therefore, under
physiological conditions, concentration of extracellular
adenosine (ectoAdo) between 0.3–1.000 nM is high enough
to activate the adenosine A1 and A2A receptors. Receptors
with a low affinity to the agonist require higher concentra-
tion of the extracellular nucleoside. Such elevated concen-
trations of ectoAdo, exceeding the highest physiological
level of 1 μM, are detected in tissues during hypoxia [7].
A1 receptors are coupled with the subfamilies Gi(1–3) and
Go of G proteins. They inhibit the adenylate cyclase
activity. Activation of these receptors results in the opening
of several types of potassium channels and closing of some
calcium channels [7–10].
Adenosine A2A and A2B receptors are coupled with Gs
proteins, which in turn activate adenylate cyclase, causing
the elevation of the cAMP level in cells [7]. It is still
unclear if the activation of the adenosine A2A receptor leads
to different results than the stimulation of the adenosine
A2B receptors. However, both subtypes differ in location
and pharmacological properties. In CNS, the adenosine A2B
receptor is widely spread, while adenosine A2A receptors
have been found only in the dopaminergic regions of the
brain.
Adenosine A3 receptors are not as well known as the
others. It is known that stimulation of that receptor leads to
the formation of inositol triphosphate (IPA3) and conse-
quently to an increase in calcium concentration in cells. The
adenosine A3 receptors are abundant in the brain, but their
amount is significantly lower than that of other adenosine
receptors [7, 9].
The adenosine receptors are bound to the cell mem-
branes of neurons, glia cells, and endothelial cells of the
brain blood vessels [7–9]. In the brain, A1 is the most
abundant type of adenosine receptor. It occurs in the neuron
synaptic membranes of such brain structures as the brain
core, hippocampus, cerebellum, spinal cord, thalamus, and
striatum [7–10]. Small amounts of mRNA of the adenosine
A2B receptor have been found in such brain structures as
the brain core, hippocampus, cerebellum, thalamus, hypo-
thalamus, and striatum. In turn, the presence of mRNA of
the adenosine A3 receptor was detected in the rat
hippocampus, thalamus, and hypothalamus [7].
The adenosine A2A receptors are abundant in striatum
and other nuclei of the basal ganglia, as well as in nucleus
accumbens and olfactory bulb, where they are always co-
localized with the dopaminergic D2 receptors. However,
presence of adenosine A2A receptor was not detected in
striatal neurons expressing D1 receptors, substance P, and
dynorfin [10]. In the rat brain, small amounts of mRNA of
that receptor have been detected in the brain core,
hippocampus, cerebellum, thalamus, and hypothalamus [7,
10]. Few adenosine A2A receptors involved in modulation
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acetylcholine, or glutamate are localized on neurons of
nucleus caudatus and pulvinar [3]. In striatum, adenosine
A2A receptors are localized mainly postsynaptically (70%),
but also presynaptically (23%), on the neuron body (3%),
and on glia cells (3%).
The dopaminergic receptors are classified into two
sub-families:
1. D1 sub-family (D1-like), which consists of D1 and D5
receptors
2. D2 sub-family (D2-like), with receptors D2, D3 and D4
The dopaminergic receptors are built with about 400
amino acids and contain seven α-helices participating in
ligand binding [11]. Signal from the activated receptor is
transmitted to the effector proteins via G proteins. The
dopaminergic cells are grouped into the dopaminergic
system pathways. The most important is the pathway
linking substantia nigra and striatum (nigrostriatal), which
produces 75% of the brain dopamine and participates in the
regulation of motor activity. Other pathways are the
mesolimbic pathway, which participates in the regulation
of emotional and cognitive functions, as well as mesocort-
ical and tubero-infundibular pathways [11].
For fulfilling the functions of dopamine, the simulta-
neous stimulation of D1 and D2 receptors is necessary, a
process called obligatory synergism. Agonists of D1 and
D2 receptors not only enhance their action, but neither of
them is efficient separately when used in the presence of the
antagonist of the other receptor [11].
It is important that in striatum the dopaminergic D1 and
D2 receptors occur on different neuron populations [12].
The majority of D1 receptors are localized on the direct
pathways between striatum and substantia nigra (direct
striatonigral pathway) [13]. However, co-localization of D2
and adenosine A2A receptors occurs only on the indirect
pathways between striatum, globus pallidus, and substantia
nigra (indirect striato-pallido-nigral pathway) [14].
Functions of adenosine and dopamine in CNS
The neurochemical and behavioral research reveals that
stimulation of pathways between striatum, globus pallidus,
and substantia nigra leads to improved mobility. These
results indicate a synergism between stimulation of D2
receptors and inhibition of adenosine A2A receptors [14].
In 1970 it was found that adenosine participates in
regulation of signal transmission in the extrapyramidal
system [15]. Currently it is known that adenosine A2A
receptors participate in the antagonistic interaction between
adenosine and dopamine and could affect the mobility
independent of D2 receptors [10]. Activation of adenosine
A2A receptors in animals results in sedation and catalepsy,
reduces the normal mobility resulting from activation of the
dopaminergic receptors, and lowers the affinity of agonists
for the dopaminergic D2 receptors [16]. The presynaptic
adenosine A2A receptors occur in the glutaminergic endings
of the core-striatum pathway of the GABA-ergic neurons or
interneurons, where their activation leads to glutamate
release. Biochemical and electrophysiological research
revealed that adenosine A2A receptors modulate the
GABA-ergic transmission in striatum and globus pallidus
[17]. Activation of adenosine A2A receptors in striatum
inhibits the GABA release and GABA-ergic transmission,
while in globus pallidus it enhances the GABA-ergic
transmission via the cAMP-dependent mechanism [1, 18].
In striatum, the adenosine A2A receptors occur also in the
cholinergic interneurons, where they modulate the activity
of A and C kinases, and consequently stimulate acetylcho-
line release [19]. Therefore, in striatum, an activation of
adenosine A2A receptors, resulting in lower transmission
depending on dopamine, disturbs the balance of neuro-
transmission described above. The progressive degenera-
tion of neurons of striatum and substantia nigra, occurring
in Parkinson’s disease, causes a decrease in the stimuli
inflow, and consequently results in the pathological
disorders of mobility called hypertonic-hypokinetic syn-
drome, characteristic of Parkinson’s disease.
New possibilities for treatment of Parkinson’s disease,
including the design of new antipsychotic drugs free from
the extrapyramidal side effects, are indicated by results
showing that CGS 21680, the agonist of the adenosine A2A
receptor, decreases the affinity of D2 receptors for
dopamine in human striatum [20–22].
Use of A2A receptor antagonists in the experimental
models of Parkinson’s disease
The milestone in the research on Parkinson’s disease was
the design of an animal model in primates, treated with 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
MPTP is converted by the B-type monoaminooxidase into
MPP+ (1-methyl-4-phenylopyridine), which is selectively
captured by the dopaminergic neurons. MPP+ inhibits the
activity of complex I of the mitochondrial respiratory chain,
decreases the ATP synthesis and enhances the formation of
superoxide radicals, which form the toxic peroxonitrites in
a reaction with nitric oxide. These processes lead to the
aggregation of α-synuclein in neurons of the substantia
nigra [23, 24]. Another animal model of Parkinson’s
disease was developed by an administration of metham-
phetamine (MTH). Administration of MTH decreases the
number of dopaminergic cells in substantia nigra and the
dopamine level in striatum and reduces the activity of
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model is obtained by an injection of 6-hydroxydopamine
into the forebrain bundle, which produces lesions of the
nigro-striatal pathway in rats [3, 25, 26].
Xanthine derivatives-antagonists of the adenosine A2A
receptors
In 1994, selective antagonists of the adenosine A2A
receptors were synthesized. Their application in the animal
models revealed that these compounds might be useful in
treatment of Parkinson’s disease [27]. The xanthine
derivatives KF17837 and KW6002 (istradefylline), which
are antagonists of the adenosine A2A receptors in nano-
molar concentrations, reveal almost 70 times higher
selectivity for A2A than for adenosine A1 receptor. It was
shown that the selective adenosine A2A receptor antagonists
(SCH 58261, KF17837, and istradefylline) in animals
decrease the symptoms of catalepsy caused by administra-
tion of haloperidol, symptoms of akinesia caused by
reserpine, and the anti-cataleptic action during administra-
tion of L-DOPA [1]. The action of the selective adenosine
A2A receptor antagonists in alleviating symptoms of
Parkinson’s disease was shown in the original animal
model of that disease [28, 29]. In that research, istradefyl-
line lowered the extrapyramidal mobility disorders caused
by MPTP in monkeys.
Bara-Jimenez et al. [30] reported that istradefylline,
either separately or co-administered with L-DOPA in a
permanent intravenous infusion in the optimal dose, did not
affect the progression of extrapyramidal syndrome. How-
ever, its co-administration with small doses of L-DOPA
caused 36% greater efficacy of anti-Parkinson response and
45% decrease in dyskinesias caused by the optimal doses of
L-DOPA. All basic symptoms of Parkinson’s syndrome, in
particular a passive tremor, were reduced after the proce-
dure. Moreover, istradefylline increased the efficacy of L-
DOPA by prolongation of its average half-life by 47 min,
without any symptoms of toxicity [30].
In the animal experiments, Gołembiowska et al. [31] had
shown that inhibition of adenosine A2A receptor in striatum
after L-DOPA administration intensified the dopamine
release from neurons. Therefore, the adenosine A2A
receptor antagonists, by increasing the therapeutic efficacy
of L-DOPA, might have a positive effect even in the early
stages of Parkinson’s disease.
Oral administration of istradefylline in the animal model
of Parkinson’s disease induced in monkeys by MPTP
improved mobility for 11 h [32], which was identical to
that of healthy animals, while L-DOPA caused hyperkine-
sia. Moreover, the use of istradefylline for 21 days did not
cause dyskinesias, which appeared during treatment with L-
DOPA. Co-administration of istradefylline and L-DOPA
increased the anti-Parkinson activity by 30% and did not
cause dyskinesias. These results suggest that istradefylline
could be efficiently used in monotherapy in patients with
the early form of Parkinson’s disease. In patients who
reveal significant mobility disorders, istradefylline can
improve the anti-Parkinson activity of L-DOPA, while not
causing dyskinesias. In patients with advanced Parkinson’s,
istradefylline reduced the “off” time. The most frequent
among rarely observed side effects was nausea, usually
occurring at the beginning of the treatment and disappear-
ing in 10 days. The only significant side effect was the
elevated concentration of lipase observed in five patients
(7.4%) [32].
In the animal model of the disease induced by MPTP,
istradefylline administered with L-DOPA or with the D2
receptor agonist quinpirole reveals not only the additive
anti-Parkinson activity, but also does not intensify dyski-
nesias [1].
Role of other antagonists of the adenosine A2A receptors
in Parkinson’s disease treatment
Recently, during the research on the anti-malaria drug
mefloquine, Weiss et al. [33] discovered that a fragment of
its molecule is an adenosine A2A receptor antagonist. Based
on that observation, they synthesized more than 2,000
different adenosine A2A receptor antagonists. In particular
VER-6947 and VER-7835 in vivo reversed the locomoto-
rial disorders caused by the D2 receptor antagonist
haloperidol [33]. In rats with brain damage induced by 6-
OHDA infusion in the medial forebrain bundle, behavioral
research was conducted with the use of the adenosine A2A
receptor antagonist SCH 58261 and the threshold dose of
L-DOPA. Long-lasting or periodically interrupted adminis-
tration of SCH 58261 (5 mg/kg) combined with L-DOPA
(3 mg/kg) caused a stable turning behavior of animals,
while treatment with L-DOPA resulted in sensitized turning
behavior [25]. Wardas [34] showed the synergic action of
L-DOPA and SCH 58261 in decreased muscular rigidity
induced in rats by reserpine. Another study showed that
these compounds significantly decreased the tremor in rats
[35]. Also, in rats the A2A receptor antagonists DMPX,
KF17837, and istradefylline cancelled catalepsy caused by
haloperidol or reserpine. Contrary to L-DOPA, the long-
term administration of selective adenosine A2A receptor
antagonists does not result in dyskinesias or lack of
response in Parkinson’s disease models induced by 6-
OHDA and MPTP.
Latest results show that ST1535 administered alone
enhanced the exploratory behavior and produced a dose-
related increase in ipsilateral rotation in unilaterally 6-
OHDA-lesioned rats. Injection of ST1535 combined with
high dose of L-DOPA caused significant contraversive
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by L-DOPA alone [26]. ST1535 administered alone
produced a dose-related increase in the locomotor activity
and tended to reverse the motor disability in MPTP-treated
common marmosets. A similar effect was observed after
treatment with a threshold dose of L-DOPA [36]. Another
adenosine A2A receptor antagonist, arylpiperazine SCH
420814, orally administrated in rats with haloperidol-
induced catalepsy revealed good pharmacokinetic proper-
ties and excellent in vivo activity [37].
Nonselective antagonists of adenosine A1 and A2A
receptors
The indirect evidence of adenosine A2A receptor involve-
ment in regulation of motor behavior is the observed
improvement in mobility after treatment with caffeine and
theophylline, nonselective antagonists of the adenosine A1/
A2 receptors [38]. This suggests that drinking concentrated
coffee might improve the mobility of patients with
Parkinson’s disease. However, the opinions on that are
contradictory. The epidemiological research indicates that
these patients usually do not drink coffee. It was found that
even a single administration of caffeine might increase the
neurotoxicity, as measured by both the activity of tyrosine
hydroxylase and the dopamine concentration in striatum
[39]. However, the long-term administration of caffeine
inhibits the neurotoxicity caused by MTH and MPTP [3,
39]. That might be explained by either inhibition of
adenosine A2A receptors or an increased amount of
adenosine A1 receptors in striatum [39].
Two large prospective epidemiological studies were
performed. The 30 years of follow-up data for a group of
8,004 men revealed that higher dietary intake of caffeine
significantly lowered incidence of PD [40]. Research by
Ascherio et al. [41] on two cohorts of men and women
further supported the protective effect of caffeine against a
risk of PD in men, while for women the effect was U-
shaped. Theophylline also decreases symptoms of Parkin-
son syndrome and elongates the “on” phase in patients with
the advanced form of Parkinson’s disease [42].
So far, there has been a lack of reliable research
indicating changes in the adenosine level in the CNS of
patients with Parkinson’s disease. There are, however, few
reports suggesting changes in the amount of adenosine
receptors in these patients. Post-mortem tests of patients
treated with dopaminergic drugs, reported by Hurley et al.
[43], revealed changes in the amount of adenosine A2A
receptor mRNA in the nucleus caudatus and pulvinar, as
well as in the substantia nigra. One could only guess that
similar effects could occur in untreated patients. Calon et al.
[44] suggested that long-lasting treatment with L-DOPA
results in an intensified synthesis of adenosine A2A
receptors in the pathway between striatum and substantia
nigra, and occurrence of dyskinesias in Parkinson’s disease
patients. In our opinion, the therapeutic effect might depend
not only on the change in the ecto-adenosine concentration
or the amount of the adenosine receptors, but also might be
linked to the disturbed ratio between adenosine and
dopamine level, since the therapeutic effect is achieved by
simultaneous use of the adenosine A2A receptor antagonists
and D2 receptor agonists.
Neuroprotective activity of antagonists of the adenosine
A2A receptor
Research on the role of adenosine receptors in treatment of
Parkinson’s disease indicates that the therapeutic effect of
their antagonistscouldbelinkedtothe neuroprotectiveaction.
The increased release of the stimulating transmitters might
play a crucial role in the death of neurons resulting from
excitotoxicity. Therefore, it should be concluded that drugs
inhibiting glutamate release might beefficient inthe treatment
of neurodegenerative diseases [45, 46]. Both adenosine A1
and A2A receptors play an important role in neuroprotection.
Chen et al. [46] showed, in an animal model of PD
induced by MPTP, that the neuroprotection is caused by
inactivation of adenosine A2A receptor with caffeine.
A similar effect is achieved with the use of several other
adenosine A2A receptor antagonists (SCH58261, KW-6002)
or by genetic inactivation of adenosine A2A receptor
expression. In rat models of Parkinson’s disease induced
by 6-hydroxydopamine (6-OHDA), a significant neuro-
protective effect was achieved by oral administration of
KW-6002, an antagonist of adenosine A2A receptor [3]. On
the other hand, inhibition of adenosine A1 receptors with 8-
cyclopenthyl-1,3-dipropylxanthine did not protect neurons.
Therefore, the neuroprotective action is coupled to the
blockade of adenosine A2A and not A1 receptors.
Neurons of knockout mice with no adenosine A2A
receptors revealed lower resistance to hypoxia and damage
caused by MPTP. The pharmacological inhibition of
adenosine A2A receptors prevented the neurotoxicity in-
duced by administration of cholic acid into striatum [45].
The strongest neuroprotection was achieved by simulta-
neous activation of adenosine A1 receptors and inhibition of
adenosine A2A receptors. That results from the opposite
action of A1 and A2A receptors during release of glutamate
and aspartate [2]. During inhibition of A2A receptors, the
main mechanisms responsible for the neuroprotection
include dilation of the blood vessels, inhibition of blood
platelet aggregation, and decrease in the amount of
neutrophils [47]. There are several other mechanisms for
the neuroprotective action of the adenosine A2A receptor
antagonists, such as a decrease in the microglia activation
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1beta) [2]. Interactions between both types of the adenosine
receptors suggest that the adenosine action mediated by
adenosine A1 receptors might be weakened when accom-
panied by adenosine A2A receptor activation. Stimulation of
the A2A part of heteromeric adenosine A1/A2A receptor,
present in the hippocampus or striatum synaptosomes,
decreases the agonist binding by A1 receptors, therefore
lowering their ability to inhibit the excitability and synaptic
transmission in hippocampus. As a result, low concen-
trations of adenosine inhibit the release of glutamate, which
is involved in neurotoxicity, while high concentrations
stimulate its release [48].
Re-uptake of glutamate by neurons and glia cells is the
main mechanism for maintaining or lowering the extracel-
lular concentration of that neurotransmitter. In striatum,
activation of adenosine A2A receptors results in an
increased concentration of extracellular glutamate, while
the adenosine A2A receptor antagonists inhibit glutamate
release from cells [49]. It was found that the selective
antagonists of adenosine A2A receptor prevent damage of
the hippocampus neurons caused by forebrain hypoxia in
gerbils and rats and decrease the size of the brain stroke
region in the model of focal ischemia during occlusion of
the middle cerebral artery [49]. Similarly, use of selective
adenosine A2A receptor antagonists (SCH 58261, ZM
241285, and CSC) decreased the region of brain damage
by the cainic, kinurenic and cholic acids [2]. The adenosine
A2A receptor antagonists affect the adenosine receptors
located on the presynaptic membrane, but do not influence
the effects of the stimulation of NMDA receptors [45]. It
was found that large doses of SCH 58261 can cause
peripheral symptoms such as lowering the blood pressure,
which leads to a decrease in brain blood flow and further
stimulation of the glutamate release.
Neuroprotective action of adenosine is also confirmed by
analysis of the effect of adenosine deaminase and adenosine
kinase inhibitors in the MHT model, as well as the influence
of the adenosine transport inhibitors on the dopamine release
and long-lasting neurotoxic effects of MHT [50]. In the 6-
OHDA and MPTP models of brain damage, istradefylline
and KF18446 revealed the neuroprotective action by
inhibiting the adenosine A2A receptors [3].
Summary
Immunohistochemical research revealed that neurons local-
ized in the basal ganglia have high amounts of adenosine
A2A receptors, which are located mainly on the indirect
striato-pallido-nigral pathway between the striatum, globus
pallidus, and substantia nigra. The animal models of
Parkinson’s disease proved that adenosine A2A receptors
are involved in the regulation of CNS. In striatum,
adenosine A2A receptors are co-localized with D2 dopami-
nergic receptors, which creates the possibility of an
antagonistic interaction between adenosine and dopamine.
Also, activation of adenosine A2A receptors inhibits the
release of GABA and the GABA-ergic transmission, while
enhancing the GABA-ergic transmission in globus pallidus
via the cAMP-dependent mechanism.
So far, the changes in the amount of adenosine in the
brains of patients with Parkinson’s disease have not been
detected. Only a few results suggest changes in the amount
of the adenosine receptors in that disease. Despite that, it
seems that the largest improvement in the mobility of
patients with Parkinson’s disease could be achieved by
simultaneous activation of the dopaminergic D2 receptors
and inhibition of adenosine A2A receptors. In the animal
models of PD, in which the symptoms were induced by
administration of MPTP to the basal ganglia, the revers-
ibility of the motor dysfunction was shown with the use of
selective adenosine A2A receptor antagonists, such as
istradefylline. That compound had proven effective, admin-
istered both in an intravenous infusion or orally. It was
reported that the adenosine A2A receptor antagonists might
improve mobility when used both in monotherapy and co-
administered with L-DOPA and agonists of the dopaminer-
gic receptors. In the combination therapy, the use of these
compounds will allow a reduction in the dose of co-
administered L-DOPA and reduced side effects. Use of
adenosine A2A receptor antagonists does not cause the
dyskinesias found in monotherapy or in the combination
therapy with L-DOPA and with agonists of the dopaminer-
gic receptors. In the additional treatment, the adenosine A2A
receptor antagonists could be used in both moderately and
significantly advanced forms of Parkinson’s disease. The
long-lasting administration of adenosine A2A receptor
antagonists did not lead to tolerance or occurrence of side
effects as is characteristic of the long-term use of L-DOPA.
Inhibition of adenosine A2A receptors not only decreases
mobility disorders, but also reveals the neuroprotective
effect, as shown in different animal models. Since adeno-
sine A2A receptors are also located in the limbic system,
hippocampus, and amygdala, these compounds might also
be helpful in psychic disorders, especially those with fear
and depression symptoms. The occurrence of these symp-
toms in patients with Parkinson’s disease might be an
additional indication for usage of the adenosine A2A
receptor antagonists.
Clinical perspectives
The adenosine A2A receptor antagonist istradefylline
entered the preclinical tests as an adjunct in the L-DOPA
310 Purinergic Signalling (2008) 4:305–312therapy in Parkinson’s disease patients [32, 51]. Recently,
phase II and III clinical studies with istradefylline were
completed [52] in North America and the European Union
in Parkinson’s disease patients who are experiencing
“wearing-off phenomenon” while taking L-DOPA alone,
or while taking L-DOPA with other Parkinson’s disease
medications. More than 1,200 patients affected by Parkin-
son’s disease participated in these tests. The research
revealed that istradefylline is well tolerated by the majority
of patients. It does not activate dyskinesias and other
changes in mobility, which have been observed during
dopaminergic adjunctive therapies. Istradefylline reduces
the “off” time, and patients remain in the longer “on” phase
with symptoms of nontroublesome dyskinesia. Another
advantage is that istradefylline and arylpiperazine might
also be administered orally based on home diaries [32, 37].
Due to its nonmotor and nondopaminergic action, istrade-
fylline might also be used as a drug in the treatment of
neuropsychiatric symptoms occurring in Parkinson’s dis-
ease. In summary, istradefylline might become an important
drug that delays, decreases, or reverses symptoms of
Parkinson’s disease. Also the neuroprotective action of
istradefylline on dopaminergic neurons is very important
and promising for its future applications.
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